Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q7RTZ2
UPID:
U17L1_HUMAN
Alternative names:
Deubiquitinating enzyme 17-like protein 1; Ubiquitin thioesterase 17-like protein 1; Ubiquitin-specific-processing protease 17-like protein 1
Alternative UPACC:
Q7RTZ2
Background:
Ubiquitin carboxyl-terminal hydrolase 17-like protein 1, also known as Deubiquitinating enzyme 17-like protein 1, plays a pivotal role in cellular processes by removing ubiquitin from specific proteins. This action is crucial for regulating cell proliferation, cell cycle progression, apoptosis, cell migration, and the cellular response to viral infection.
Therapeutic significance:
Understanding the role of Ubiquitin carboxyl-terminal hydrolase 17-like protein 1 could open doors to potential therapeutic strategies.